AVEO Pharmaceuticals, Inc.-Product Pipeline Review-2015

AVEO Pharmaceuticals, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC06961CDB
  • |
  • Pages: 63
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AVEO Pharmaceuticals, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'AVEO Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AVEO Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of AVEO Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of AVEO Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the AVEO Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate AVEO Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of AVEO Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the AVEO Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of AVEO Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of AVEO Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of AVEO Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

AVEO Pharmaceuticals, Inc. Snapshot 6

AVEO Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

AVEO Pharmaceuticals, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

AVEO Pharmaceuticals, Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Pipeline Products-Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

AVEO Pharmaceuticals, Inc.-Pipeline Products Glance 16

AVEO Pharmaceuticals, Inc.-Late Stage Pipeline Products 16

Filing rejected/Withdrawn Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

AVEO Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

AVEO Pharmaceuticals, Inc.-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

AVEO Pharmaceuticals, Inc.-Drug Profiles 22

tivozanib 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

ficlatuzumab 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

AV-203 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AV-380 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AV-232 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

GP-369 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

AV-370 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody to Antagonize FGFR1 for Cancer 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Monoclonal Antibody to Antagonize FGFR4 for Cancer 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Monoclonal Antibody to Target Notch2 for Cancer 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Monoclonal Antibody to Target Notch3 for Cancer 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Monoclonal Antibody to Target Notch4 for Cancer 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

AVEO Pharmaceuticals, Inc.-Pipeline Analysis 38

AVEO Pharmaceuticals, Inc.-Pipeline Products by Target 38

AVEO Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 40

AVEO Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 41

AVEO Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 42

AVEO Pharmaceuticals, Inc.-Recent Pipeline Updates 44

AVEO Pharmaceuticals, Inc.-Dormant Projects 52

AVEO Pharmaceuticals, Inc.-Discontinued Pipeline Products 53

Discontinued Pipeline Product Profiles 53

AV-412 53

tivozanib 53

AVEO Pharmaceuticals, Inc.-Company Statement 54

AVEO Pharmaceuticals, Inc.-Locations And Subsidiaries 61

Head Office 61

Other Locations & Subsidiaries 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

AVEO Pharmaceuticals, Inc., Key Information 6

AVEO Pharmaceuticals, Inc., Key Facts 6

AVEO Pharmaceuticals, Inc.-Pipeline by Indication, 2015 8

AVEO Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 10

AVEO Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 11

AVEO Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 12

AVEO Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 13

AVEO Pharmaceuticals, Inc.-Out-Licensed Products in Pipeline, 2015 14

AVEO Pharmaceuticals, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 15

AVEO Pharmaceuticals, Inc.-Filing rejected/Withdrawn, 2015 16

AVEO Pharmaceuticals, Inc.-Phase III, 2015 17

AVEO Pharmaceuticals, Inc.-Phase II, 2015 18

AVEO Pharmaceuticals, Inc.-Phase I, 2015 19

AVEO Pharmaceuticals, Inc.-Preclinical, 2015 20

AVEO Pharmaceuticals, Inc.-Discovery, 2015 21

AVEO Pharmaceuticals, Inc.-Pipeline by Target, 2015 39

AVEO Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 40

AVEO Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 41

AVEO Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 43

AVEO Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 44

AVEO Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 52

AVEO Pharmaceuticals, Inc.-Discontinued Pipeline Products, 2015 53

AVEO Pharmaceuticals, Inc., Subsidiaries 61

List of Figures

AVEO Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 8

AVEO Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 10

AVEO Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 11

AVEO Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 12

AVEO Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 38

AVEO Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 40

AVEO Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 41

AVEO Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc. - Key Therapeutics; AVEO Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; AVEO Pharmaceuticals, Inc. - News; AVEO Pharmaceuticals, Inc. - Latest Updates; AVEO Pharmaceuticals, Inc. - Pipeline; AVEO Pharmaceuticals, Inc. - Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 106635
Site License
USD 3000 INR 213270
Corporate User License
USD 4500 INR 319905



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com